Bifemelane hydrochloride

Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a Ki of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a Ki of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease.

Product information

CAS Number: 62232-46-6

Molecular Weight: 305.84

Formula: C18H24ClNO

Synonym:

MCI-2016

Chemical Name: [4-(2-benzylphenoxy)butyl](methyl)amine; chlorohydrogen

Smiles: Cl.CNCCCCOC1=CC=CC=C1CC1C=CC=CC=1

InChiKey: MEAHDXWXNNDSAK-UHFFFAOYSA-N

InChi: InChI=1S/C18H23NO.ClH/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16;/h2-6,9-12,19H,7-8,13-15H2,1H3;1H

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 250 mg/mL (817.42 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Bifemelane inhibits MAO-A in a dose-dependent manner, with Kis of 4.2±0.2 and 14.1±0.7 μM in human brain synaptosomes and human liver mitochondria respectively. Bifemelane inhibits MAO-B activities in a dose-dependent manner, with Kis of 46.0±3.6 and 65.2±7.0 μM in human brain synaptosomes and human liver mitochondria respectively.

In Vivo:

Bifemelane (20-80 mg/kg; i.p.) dose-dependently decreases exploratory activity in the open field test. Bifemelane (20-80 mg/kg; i.p.) decreases immobility time in the forced swim test, although is not clearly dosedependent and has already reached ceiling at 20 mg/kg.

References:

1. Naoi M, et, al. 4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan; 50(1): 243-7.
2. Fasipe OJ, et, al. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep. 2019 Jan 9; 6:95-110.
3. Moryl E, et, al. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol. 1993 Jun; 72(6): 394-7.

Products are for research use only. Not for human use.